Clinical development and trial testing of vesleteplirsen (SRP-5051) for Duchenne muscular dystrophy (DMD) was stopped, with ...

Gene therapy can effectively treat various diseases, but for some debilitating conditions like muscular dystrophies there is ...

Kuntz, MD, was a fellow about 45 years ago, there were few more devastating diagnoses than Duchenne muscular dystrophy (DMD).

Sarepta will discontinue its next generation of exon-skipping drugs for Duchenne muscular dystrophy over safety concerns, in ...

The EMBARK Phase 3 study for Elevidys, Sarepta Therapeutics’ gene therapy for Duchenne muscular dystrophy, was published this month in Nature Medicine. The paper largely reiterates what’s ...

Opens in a new tab or window SAVANNAH, Ga. -- Delandistrogene moxeparvovec (Elevidys), a gene therapy approved to treat Duchenne muscular dystrophy, missed its primary endpoint but differences ...

Sarepta Therapeutics has decided not to continue the development of vesleteplirsen, a follow-up to its Duchenne muscular dystrophy (DMD) therapy Exondys 51. The drug – formerly known as SRP-5051 ...

People hit the road for a short race Saturday to support research into Duchenne muscular dystrophy. The GR .1K was held ...

Elevidys sales have increased since the FDA made a controversial choice to expand the therapy's use. Meanwhile, Sarepta is ...

Investors consider Dyne Therapeutics' treatments for muscle diseases and strong cash position as a speculative Buy ...

When Mats died of a terminal disease, messages flooded to his parents from the community of gamers with whom he had an unknown, vibrant life. Good luck keeping your eyes dry.

Zinc supplementation showed limited benefits in improving muscle health and hydration in boys with DMD. Nearly 30% of participants had low zinc levels initially, with slight improvement post ...